Ascendis Pharma A/S (ASND) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
ASND Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Ascendis Pharma A/S (ASND) trades at a price-to-earnings ratio of -55.5x, with a stock price of $235.90 and trailing twelve-month earnings per share of $-3.71.
Compared to the Healthcare sector median P/E of 22.1x, ASND trades at a 351% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, ASND trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ASND DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ASND P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $20B | 15.6 | -Best | +4173%Best | |
| $6B | 24.7 | -Best | -34% | |
| $4B | 9.4Lowest | -Best | +68% | |
| $9B | 42.2 | -Best | +128% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Full ASND Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ASND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASND Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ASND vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
Is ASND stock overvalued or undervalued?
ASND current P/E: -55.5x. 5-year average P/E: N/A. Percentile: N/A.
How does ASND's valuation compare to peers?
Ascendis Pharma A/S P/E of -55.5x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is ASND's PEG ratio?
ASND PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.